Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Harvard Business School
Federal Trade Commission
US Department of Justice
Healthtrust
Fuji
Teva
Baxter
Medtronic

Generated: January 19, 2018

DrugPatentWatch Database Preview

Fosaprepitant dimeglumine - Generic Drug Details

« Back to Dashboard

What are the generic sources for fosaprepitant dimeglumine and what is the scope of fosaprepitant dimeglumine patent protection?

Fosaprepitant dimeglumine
is the generic ingredient in two branded drugs marketed by Merck And Co Inc and Fresenius Kabi Usa, and is included in two NDAs. There is one patent protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Fosaprepitant dimeglumine has thirty-six patent family members in twenty-seven countries.

There are nine drug master file entries for fosaprepitant dimeglumine. One supplier is listed for this compound. There is one tentative approval for this compound.
Summary for fosaprepitant dimeglumine
Tentative approvals for FOSAPREPITANT DIMEGLUMINE
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ Subscribe150MGINJECTABLE;INJECTION

US Patents and Regulatory Information for fosaprepitant dimeglumine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 206197-001 Jun 9, 2016 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for fosaprepitant dimeglumine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for fosaprepitant dimeglumine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists ➤ Subscribe
5,716,942 Treatment of migraine with morpholine tachykinin receptor antagonists ➤ Subscribe
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for fosaprepitant dimeglumine

Supplementary Protection Certificates for fosaprepitant dimeglumine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/021 United Kingdom ➤ Subscribe PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
C0019 France ➤ Subscribe PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Deloitte
AstraZeneca
UBS
Boehringer Ingelheim
Teva
Daiichi Sankyo
Julphar
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot